Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis

Fundamental and Clinical Pharmacology

Volumn 23, Issue 5, 2009, Pages 595-600

  Derdemezis, Christos S ^a   Filippatos, Theodosios D ^a   Voulgari, Paraskevi V ^a   Tselepis, Alexandros D ^b   Drosos, Alexandros A ^a   Kiortsis, Dimitrios N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adiponectin; Anti TNF; Infliximab; Leptin; Rheumatoid arthritis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; INFLIXIMAB; LEPTIN; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; ENZYME IMMUNOASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADIPONECTIN; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEPTIN; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69949166663     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00717.x     Document Type: Article

References (33)

1. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. (2005) 115 911 919.
2. Halaas J.L., Gajiwala K.S., Maffei M., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science (1995) 269 543 546.
3. Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. (2004) 24 29 33.
4. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. (1999) 130 478 486.
5. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41 1552 1563.
6. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The armada trial. Arthritis Rheum. (2003) 48 35 45.
7. Otero M., Lago R., Gomez R., et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) 65 1198 1201.
8. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 259 87 91.
9. Serelis J., Kontogianni M.D., Katsiougiannis S., Bletsa M., Tektonidou M.G., Skopouli F.N. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin. Rheumatol. (2008) 27 795 797.
10. Nishida K., Okada Y., Nawata M., Saito K., Tanaka Y. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (ifx), an anti-TNF-alpha antibody. Endocr. J. (2008) 55 213 216.
11. Harle P., Sarzi-Puttini P., Cutolo M., Straub R.H. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) 65 970 971.
12. Komai N., Morita Y., Sakuta T., Kuwabara A., Kashihara N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod. Rheumatol. (2007) 17 385 390.
13. Prevoo M.L., van 't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. (1995) 38 44 48.
14. Felson D.T., Anderson J.J., Boers M., et al. The american college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum. (1993) 36 729 740.
15. Kiortsis D.N., Nikas S., Hatzidimou K., Tsianos E., Elisaf M.S. Lipid-lowering drugs and serum liver enzymes: The effects of body weight and baseline enzyme levels. Fundam. Clin. Pharmacol. (2003) 17 491 494.
16. Busso N., So A., Chobaz-Peclat V., et al. Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J. Immunol. (2002) 168 875 882.
17. Ehling A., Schaffler A., Herfarth H., et al. The potential of adiponectin in driving arthritis. J. Immunol. (2006) 176 4468 4478.
18. Bokarewa M., Bokarew D., Hultgren O., Tarkowski A. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62 952 956.
19. Anders H.J., Rihl M., Heufelder A., Loch O., Schattenkirchner M. Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism (1999) 48 745 748.
20. Popa C., Netea M.G., Radstake T.R., van Riel P.L., Barrera P., van der Meer J.W. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann. Rheum. Dis. (2005) 64 1195 1198.
21. Yamasaki S., Nakashima T., Kawakami A., et al. Cytokines regulate fibroblast-like synovial cell differentiation to adipocyte-like cells. Rheumatology (Oxford) (2004) 43 448 452.
22. Berner H.S., Lyngstadaas S.P., Spahr A., et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone (2004) 35 842 849.
23. Schaffler A., Ehling A., Neumann E., et al. Adipocytokines in synovial fluid. JAMA (2003) 290 1709 1710.
24. Voulgari P.V., Alamanos Y., Nikas S.N., Bougias D.V., Temekonidis T.I., Drosos A.A. Infliximab therapy in established rheumatoid arthritis: An observational study. Am. J. Med. (2005) 118 515 520.
25. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how "High-grade" Systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation (2003) 108 2957 2963.
26. Argyropoulou M.I., Kiortsis D.N., Daskas N., et al. Distensibility and pulse wave velocity of the thoracic aorta in patients with juvenile idiopathic arthritis: an MRI study. Clin. Exp. Rheumatol. (2003) 21 794 797.
27. Bernstein L.E., Berry J., Kim S., Canavan B., Grinspoon S.K. Effects of etanercept in patients with the metabolic syndrome. Arch. Intern. Med. (2006) 166 902 908.
28. Maki-Petaja K.M., Hall F.C., Booth A.D., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation (2006) 114 1185 1192.
29. Kiortsis D.N., Mavridis A.K., Vasakos S., Nikas S.N., Drosos A.A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. (2005) 64 765 766.
30. Kiortsis D.N., Mavridis A.K., Filippatos T.D., Vasakos S., Nikas S.N., Drosos A.A. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. (2006) 33 921 923.
31. Edrees A.F., Misra S.N., Abdou N.I. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: Correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin. Exp. Rheumatol. (2005) 23 469 474.
32. Charles P., Elliott M.J., Davis D., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. (1999) 163 1521 1528.
33. Barrera P., Joosten L.A.B., den Broeder A.A., van de Putte L.B.A., van Riel P.L.C.M., van den Berg W.B. Effects of treatment with a fully human anti-tumour necrosis factor {alpha} monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF{alpha} in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2001) 60 660 669.